
	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Numerator:
(Loss) income from continuing operations	$	(26,031)	$	48,165	$	(53,010)	$	(156,230)
Less: Net loss attributable to noncontrolling interests	(386)		(266)		(498)		(221)

Net (loss) income from continuing operations available to common stockholders, basic	(25,645)		48,431		(52,512)		(156,009)
Add: Interest expense and amortization of debt discount and issuance costs for exchangeable notes, net of tax	—		2,526		—		—

Net (loss) income from continuing operations available to common stockholders, diluted	$	(25,645)	$	50,957	$	(52,512)	$	(156,009)
Denominator:
Basic weighted-average common shares outstanding	403,618		394,580		399,406		390,616
Add: Dilutive effect of restricted stock awards	—		1,340		—		—
Add: Dilutive effect of exchangeable notes	—		33,333		—		—

Diluted weighted-average common shares outstanding	403,618		429,253		399,406		390,616
(Loss) income per share from continuing operations:
Basic	$	(0.06)	$	0.12	$	(0.13)	$	(0.40)
Diluted	$	(0.06)	$	0.12	$	(0.13)	$	(0.40)

Basic earnings per share is computed by dividing net income from continuing operations available to common stockholders by the weighted-average number of common shares outstanding during each period. Diluted earnings per share is computed by dividing net income from continuing operations available to common stockholders by the weighted-average number of common shares outstanding plus the effect of all dilutive common stock equivalents during each period. The diluted weighted-average common shares outstanding calculation excludes 10 million and 3 million of dilutive restricted stock awards for the three and nine months ended September 30, 2026, respectively, and 4 million of dilutive restricted stock awards for the nine months ended September 30, 2025, as their effect would be anti-dilutive given the net loss incurred in the period. In addition, the calculation of diluted weighted-average common shares outstanding excludes the impact of 3 million and 9 million of anti-dilutive stock options and restricted stock awards for the three and nine months ended September 30, 2026, respectively, and 8 million and 1 million of anti-dilutive stock options and restricted stock awards for the three and nine months ended September 30, 2025, respectively.

We have used the if-converted method for calculating any potential dilutive effect of the Exchangeable Notes on our diluted net income per share. Under the if-converted method, the 2025 Exchangeable Notes and 2026 Exchangeable Notes are assumed to be converted at the beginning of each period they were outstanding and the 2031 Exchangeable Notes are assumed to be converted at the issuance date of May 18, 2026. The resulting common shares are included in the denominator of the diluted earnings per share calculation for the entire period being presented and interest expense, net of tax, recorded in connection with the Exchangeable Notes is added back to the numerator, only in the periods in which such effect is dilutive. The approximately 67 million resulting common shares related to the 2031 Exchangeable Notes for both the three and nine months ended September 30, 2026, and approximately 42 million resulting common shares related to the then-outstanding Exchangeable Notes for the nine months ended September 30, 2025, are not included in the dilutive weighted-average common shares outstanding calculation as their effect would be anti-dilutive given the net loss incurred in the periods.